Bioreclamation and CelsisIVT Combine to Create BioreclamationIVT
News Aug 29, 2013
Bioreclamation Group, Inc. announced it has acquired Celsis In Vitro Technologies (“CelsisIVT”), a division of Celsis International Ltd. and a provider of in vitro products for the study of drug metabolism and toxicity. Brown Gibbons Lang & Company represented the Maryland-based CelsisIVT in the transaction. Terms of the deal were not disclosed.
The two companies will combine to become BioreclamationIVT, creating a one-stop shop offering a complete range of biological tools needed to pursue new drug discovery and development. The combined Companies’ highly specialized products enable researchers to better understand the pharmacokinetics and metabolism of newly discovered compounds. BioreclamationIVT’s sophisticated sourcing and exceptional quality control processes help reduce the time and cost of screening drug compounds in early-stage drug discovery and development.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018